Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.

Ascough S, Vlachantoni I, Kalyan M, Haijema BJ, Wallin-Weber S, Dijkstra-Tiekstra M, Ahmed MS, van Roosmalen M, Grimaldi R, Zhang Q, Leenhouts K, Openshaw PJ, Chiu C.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):481-492. doi: 10.1164/rccm.201810-1921OC.

2.

Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier PJM, van Kuppeveld FJM, Haijema BJ, de Haan CAM.

J Virol. 2016 Jun 10;90(13):5965-5977. doi: 10.1128/JVI.00235-16. Print 2016 Jul 1.

3.

Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.

Widjaja I, Rigter A, Jacobino S, van Kuppeveld FJ, Leenhouts K, Palomo C, Melero JA, Leusen JH, Haijema BJ, Rottier PJ, de Haan CA.

PLoS One. 2015 Jun 24;10(6):e0130829. doi: 10.1371/journal.pone.0130829. eCollection 2015.

4.

Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.

Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F.

Vaccine. 2014 May 19;32(24):2904-10. doi: 10.1016/j.vaccine.2014.02.019. Epub 2014 Mar 2.

5.

Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications.

Van Braeckel-Budimir N, Haijema BJ, Leenhouts K.

Front Immunol. 2013 Sep 17;4:282. doi: 10.3389/fimmu.2013.00282. eCollection 2013.

6.

A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.

Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, Rottier PJ, Haijema BJ, de Haan CA.

PLoS One. 2013 Aug 12;8(8):e71072. doi: 10.1371/journal.pone.0071072. eCollection 2013.

7.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
8.

Manipulation of the coronavirus genome using targeted RNA recombination with interspecies chimeric coronaviruses.

de Haan CA, Haijema BJ, Masters PS, Rottier PJ.

Methods Mol Biol. 2008;454:229-36. doi: 10.1007/978-1-59745-181-9_17.

PMID:
19057874
9.

Gain, preservation, and loss of a group 1a coronavirus accessory glycoprotein.

Lorusso A, Decaro N, Schellen P, Rottier PJ, Buonavoglia C, Haijema BJ, de Groot RJ.

J Virol. 2008 Oct;82(20):10312-7. doi: 10.1128/JVI.01031-08. Epub 2008 Jul 30.

10.

Cleavage of group 1 coronavirus spike proteins: how furin cleavage is traded off against heparan sulfate binding upon cell culture adaptation.

de Haan CA, Haijema BJ, Schellen P, Wichgers Schreur P, te Lintelo E, Vennema H, Rottier PJ.

J Virol. 2008 Jun;82(12):6078-83. doi: 10.1128/JVI.00074-08. Epub 2008 Apr 9.

11.

The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins.

van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Verheije MH, Bosch BJ, Balzarini J, Egberink HF.

J Antimicrob Chemother. 2007 Oct;60(4):741-9. Epub 2007 Aug 18.

PMID:
17704516
12.

Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture.

van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Peumans WJ, Van Damme EJ, Delputte PL, Balzarini J, Egberink HF.

Antiviral Res. 2007 Oct;76(1):21-9. Epub 2007 May 21.

PMID:
17560666
13.

Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and nonfluorescent low-density microarray.

de Souza Luna LK, Heiser V, Regamey N, Panning M, Drexler JF, Mulangu S, Poon L, Baumgarte S, Haijema BJ, Kaiser L, Drosten C.

J Clin Microbiol. 2007 Mar;45(3):1049-52. Epub 2007 Jan 17.

14.

Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.

W├╝rdinger T, Verheije MH, Broen K, Bosch BJ, Haijema BJ, de Haan CA, van Beusechem VW, Gerritsen WR, Rottier PJ.

J Virol. 2005 Dec;79(24):15314-22.

15.

Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor.

de Haan CA, Li Z, te Lintelo E, Bosch BJ, Haijema BJ, Rottier PJ.

J Virol. 2005 Nov;79(22):14451-6.

16.
17.

Coronaviruses as vectors: stability of foreign gene expression.

de Haan CA, Haijema BJ, Boss D, Heuts FW, Rottier PJ.

J Virol. 2005 Oct;79(20):12742-51.

18.

Transformation proteins and DNA uptake localize to the cell poles in Bacillus subtilis.

Hahn J, Maier B, Haijema BJ, Sheetz M, Dubnau D.

Cell. 2005 Jul 15;122(1):59-71.

19.

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ.

Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60. Epub 2004 May 18.

21.

Switching species tropism: an effective way to manipulate the feline coronavirus genome.

Haijema BJ, Volders H, Rottier PJ.

J Virol. 2003 Apr;77(8):4528-38.

22.

A ComGA-dependent checkpoint limits growth during the escape from competence.

Haijema BJ, Hahn J, Haynes J, Dubnau D.

Mol Microbiol. 2001 Apr;40(1):52-64.

23.

Role of enzymes of homologous recombination in illegitimate plasmid recombination in Bacillus subtilis.

Meima R, Haijema BJ, Dijkstra H, Haan GJ, Venema G, Bron S.

J Bacteriol. 1997 Feb;179(4):1219-29.

24.
25.

Regulated expression of the dinR and recA genes during competence development and SOS induction in Bacillus subtilis.

Haijema BJ, van Sinderen D, Winterling K, Kooistra J, Venema G, Hamoen LW.

Mol Microbiol. 1996 Oct;22(1):75-85.

PMID:
8899710
29.
30.

Expression of the ATP-dependent deoxyribonuclease of Bacillus subtilis is under competence-mediated control.

Haijema BJ, Hamoen LW, Kooistra J, Venema G, van Sinderen D.

Mol Microbiol. 1995 Jan;15(2):203-11.

PMID:
7746142
31.

The Bacillus subtilis addAB genes are fully functional in Escherichia coli.

Kooistra J, Haijema BJ, Venema G.

Mol Microbiol. 1993 Mar;7(6):915-23.

PMID:
8387145

Supplemental Content

Loading ...
Support Center